Stockscreener 앱 받기
82.56
2.09%
-1.76
시간 외 거래:
82.69
0.13
+0.16%
전일 마감가:
$84.32
열려 있는:
$84.44
하루 거래량:
16.24M
Relative Volume:
1.38
시가총액:
$143.80B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
23.00
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
-5.69%
1개월 성능:
-17.69%
6개월 성능:
-34.99%
1년 성능:
-38.04%
1일 변동 폭
$81.97
$84.44
1주일 범위
$81.97
$88.30
52주 변동 폭
$81.97
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Why is Abbott Laboratories stock down today? - Traders Union
Abbott Stock Down 38% in 2026: Does the $23 Billion Exact Sciences Acquisition Change the Math? - TIKR.com
Abbott Laboratories trades at decade low with growth and dividend streak, poised for EPS boost by 2028-29. - Pluang
Abbott: Three Supercycles, Mispriced At A 10-Year Low - Seeking Alpha
Abbott Laboratories stock (US0028241000): Q1 earnings beat estimates with $11.16B revenue - AD HOC NEWS
Abbott Laboratories stock (US0028241000): Kepler Cheuvreux Suisse buys new stake - AD HOC NEWS
Wearable Skin Patch Market Size Propelled by 12.8% CAGR | - openPR.com
Implantable Medical Devices Market Is Going to Boom | Medtronic, Abbott Laboratories - openPR.com
Lateral Flow Assay Component Market Is Going to Boom | Abbott Laboratories, BD - openPR.com
A Look At Abbott Laboratories (ABT) Valuation After Mixed Q1 Results And Baby Formula Legal Ruling - Yahoo Finance
Is It Time To Reconsider Abbott Laboratories (ABT) After The Recent Share Price Slump? - simplywall.st
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress - The Motley Fool
Abbott Laboratories Hires PhronesisDC on Tax Policy - Legis1
Abbott Laboratories Is On Sale, Don't Overlook It - Seeking Alpha
Abbott Laboratories: Mispriced Growth Behind Near-Term Noise? - TradingView
Abbott Laboratories stock (US0028241000): Shares hit 52-week low amid sector weakness and valuation - AD HOC NEWS
Abbott ends six-session losing streak - MSN
ABT Stock Quote Price and Forecast - CNN
Pay Less, Gain More: RMD, MDT Top Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock (ABT) Closed Down by 3.22% on May 8: A Full Analysis - TradingKey
Abbott’s BurstDR Trial Targets Painful Diabetic Neuropathy: What Investors Should Watch - TipRanks
Abbott Laboratories stock hits 52-week low at $86.15 By Investing.com - Investing.com Canada
Abbott Laboratories stock hits 52-week low at $86.15 - Investing.com
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook - Yahoo Finance
Abbott Laboratories Stock: Analyst Estimates & Ratings - Barchart.com
Abbott Laboratories (NYSE:ABT) Presents a Decent Value Opportunity After 21% Pullback - ChartMill
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
Medtronic or Abbott Laboratories: Which Stock Has More Upside? - Trefis
Between Medtronic and Abbott Laboratories, Which Stock Looks Set to Break Out? - Trefis
Immunoassay Market Competitive Analysis to 2031 | Abbott, - openPR.com
Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness? - Yahoo Finance
What Abbott Laboratories (ABT)'s New AI Cardiac Imaging, Trial Data and Share Plan Mean For Shareholders - simplywall.st
Abbott ends six-session losing streak (ABT:NYSE) - Seeking Alpha
Abbott Cardiac Data Sheds Light On Heart Rhythm Pipeline And Earnings Story - Yahoo Finance
Abbott loses appeal of nearly $500 million infant formula verdict - Crain's Chicago Business
Assessing Abbott Laboratories (ABT) Valuation After Prolonged Share Price Weakness - simplywall.st
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $109 - Moomoo
Abbott stock is trading at 52-week lows but insiders are gobbling up shares of this blue-chip dividend payer - MSN
Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula - Chicago Tribune
Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payer - Barchart.com
Missouri appeals court upholds $495M ruling against Abbott in baby formula case - Seeking Alpha
Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook - Traders Union
Bioabsorbable Stents Industry Projected to Grow at 10.2% CAGR, - openPR.com
Abbott Laboratories Pick of the Week at Smart Insider Following CFO Stock Purchase - marketscreener.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott gets FDA nod, CE mark for AI-enabled imaging device - MedTech Dive
Abbott Laboratories: performance and outlook - Business Recorder
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Globe and Mail
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.01%
자본화:
|
볼륨(24시간):